• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Outcomes in Randomized Controlled Trials of Therapeutic Interventions for Multiple Myeloma: a Systematic Review

by | Oct 6, 2024 | Publications

Crit Rev Oncol Hematol. 2024 Oct 3:104529. doi: 10.1016/j.critrevonc.2024.104529. Online ahead of print. ABSTRACT PURPOSE: Many clinical trials of therapeutic interventions for multiple myeloma do not use patient important outcomes and rely on the use of surrogate...

Immunoglobulin D-Lambda Multiple Myeloma Initially Presenting in the Sphenoid Sinus, Orbital Apex, and Skull Base: A Systematic Review with a Case Report

by | Oct 2, 2024 | Publications

J Neurol Surg Rep. 2024 Sep 16;85(3):e144-e155. doi: 10.1055/s-0044-1790589. eCollection 2024 Jul. ABSTRACT Objectives Multiple myeloma (MM) with initial manifestations in the sphenoid sinus, orbital apex, and skull base is exceedingly rare. A systematic review was...

Quadruplet regimens for patients with newly diagnosed multiple myeloma: A systematic review and meta-analysis

by | Oct 1, 2024 | Publications

Blood Adv. 2024 Sep 30:bloodadvances.2024014139. doi: 10.1182/bloodadvances.2024014139. Online ahead of print. ABSTRACT Quadruplet regimens (anti-CD38 monoclonal antibodies (mAbs) with proteosome inhibitor (PI) and immunomodulatory (IMID) drugs) are increasingly being...

Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria

by | Sep 24, 2024 | Publications

Leuk Lymphoma. 2024 Sep 24:1-10. doi: 10.1080/10428194.2024.2395440. Online ahead of print. ABSTRACT Patients with certain subsets of multiple myeloma continue to have poor outcomes and are in need of novel treatment approaches. Strict eligibility criteria for...

Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis

by | Sep 18, 2024 | Publications

PLoS One. 2024 Sep 6;19(9):e0308463. doi: 10.1371/journal.pone.0308463. eCollection 2024. ABSTRACT INTRODUCTION: Patients with multiple myeloma (MM) face heightened infection susceptibility, particularly severe risks from COVID-19. This study, the first systematic...

Efficacy of daratumumab on multiple myeloma patients with renal insufficiency: a systematic review and meta-analysis

by | Sep 18, 2024 | Publications

Hematology. 2024 Dec;29(1):2399430. doi: 10.1080/16078454.2024.2399430. Epub 2024 Sep 9. ABSTRACT BACKGROUND: Renal insufficiency (RI) is a key factor affecting the prognosis of multiple myeloma (MM) patients. Because the benefit of daratumumab for treating MM...
« Older Entries
Next Entries »

Recent Content

  • Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
  • Hexamethylene amiloride induces lysosome-mediated cell death in multiple myeloma through transcription factor E3
  • Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study
  • Black Patients With Myeloma Face Taste, Skin Side Effects from Talvey
  • ASH 2024: Expert Discusses Challenges, Future Research Opportunities With Bispecific Antibodies in Multiple Myeloma
  • Blenrep Combo Improves Survival in Relapsed/Refractory Multiple Myeloma
  • Pseudokinase TRIB3 stabilizes SSRP1 via USP10-mediated deubiquitination to promote multiple myeloma progression
  • Phase 3 GMMG-HD7 Trial: Assessing the Impact of Isatuximab on MRD Negativity and PFS in Multiple Myeloma
  • Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma
  • ASH 2024: Circulating Tumor Cells Can Serve as Biomarker for Poor Outcomes in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT